Howard J Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5178970/publications.pdf

Version: 2024-02-01

471509 434195 1,099 46 17 31 citations h-index g-index papers 48 48 48 2347 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clinical Cancer Research, 2017, 23, 7521-7530.	7.0	144
2	Pan-cancer analysis of advanced patient tumors reveals interactions between the rapy and genomic landscapes. Nature Cancer, 2020, $1,452-468$.	13.2	103
3	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	1.2	92
4	Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2016, 27, 8-19.	0.5	87
5	Application of a Neural Network Whole Transcriptome–Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. JAMA Network Open, 2019, 2, e192597.	5.9	67
6	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	7.0	50
7	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. Genetics in Medicine, 2020, 22, 1892-1897.	2.4	42
8	Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. Journal of Gastrointestinal Oncology, 2014, 5, 247-52.	1.4	42
9	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2016, 15, 179-185.	2.3	38
10	Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. Journal of Liposome Research, 1998, 8, 299-335.	3.3	34
11	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	2.0	34
12	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Journal of Physical Education and Sports Management, 2019, 5, a003681.	1.2	33
13	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	1.2	30
14	Colonoscopy after CT-diagnosed acute diverticulitis: Is it really necessary?. Canadian Journal of Surgery, 2015, 58, 226-231.	1.2	24
15	Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes. Clinical Colorectal Cancer, 2016, 15, 16-23.	2.3	20
16	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 552-554.	1.3	19
17	Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a002626.	1.2	18
18	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 262-268.e1.	2.3	17

#	Article	IF	CITATIONS
19	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Journal of Physical Education and Sports Management, 2018, 4, a002535.	1.2	16
20	Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. Npj Precision Oncology, 2018, 2, 8.	5.4	15
21	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 25-30.	2.3	14
22	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. Clinical Cancer Research, 2021, 27, 522-531.	7.0	14
23	Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. Journal of Oncology Practice, 2009, 5, 153-158.	2.5	13
24	Comparison of Toxicity Experienced by Older Versus Younger Patients Enrolled in Breast Cancer Clinical Trials. Clinical Breast Cancer, 2015, 15, 73-79.	2.4	13
25	Matching methods in precision oncology: An introduction and illustrative example. Molecular Genetics & Camp; Genomic Medicine, 2021, 9, e1554.	1.2	13
26	Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. Clinical Colorectal Cancer, 2016, 15, 352-359.e1.	2.3	12
27	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 196-201.	1.3	12
28	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	4.5	11
29	Clinical and cost outcomes following genomicsâ€informed treatment for advanced cancers. Cancer Medicine, 2021, 10, 5131-5140.	2.8	8
30	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1110-1117.	1.5	7
31	IgG4-Related Disease as Mimicker of Malignancy. SN Comprehensive Clinical Medicine, 2021, 3, 1904-1913.	0.6	7
32	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. JNCI Cancer Spectrum, 2020, 4, pkaa045.	2.9	6
33	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	1.9	6
34	Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health, 2022, 25, 1371-1380.	0.3	6
35	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. Cancer Medicine, 2020, 9, 6507-6514.	2.8	5
36	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Journal of Physical Education and Sports Management, 2020, 6, a004713.	1.2	5

#	Article	IF	CITATIONS
37	Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 429-436.	1.3	4
38	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. Journal of Community Genetics, 2022, 13, 523-538.	1.2	4
39	Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. Journal of Physical Education and Sports Management, 2019, 5, a002659.	1.2	3
40	Surveillance for asymptomatic recurrence in resected stage III colon cancer: does it result in a more favorable outcome?. Journal of Gastrointestinal Oncology, 2015, 6, 268-73.	1.4	3
41	A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. Archives of Clinical Neuropsychology, 2020, 35, 226-232.	0.5	2
42	Acute gout episodes during treatment with capecitabine: a case report. Gastrointestinal Cancer Research: GCR, 2014, 7, 59-60.	0.7	2
43	FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment. Current Oncology, 2022, 29, 402-410.	2.2	1
44	Viral Disease Goes Viral: Characterizing How Cancer Patients Use Internet Resources for COVID-19 Information. Journal of Cancer Education, 2023, 38, 431-439.	1.3	1
45	Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment. JCO Oncology Practice, 2021, 17, OP.20.00810.	2.9	0
46	Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program. JAMA Network Open, 2021, 4, e2120301.	5.9	0